KRS Capital Management LLC Acquires 20 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

KRS Capital Management LLC lifted its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.5% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,317 shares of the medical research company’s stock after buying an additional 20 shares during the quarter. KRS Capital Management LLC’s holdings in Thermo Fisher Scientific were worth $685,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in the stock. Seven Eight Capital LP raised its stake in Thermo Fisher Scientific by 29.4% during the 2nd quarter. Seven Eight Capital LP now owns 2,586 shares of the medical research company’s stock valued at $1,430,000 after purchasing an additional 588 shares during the period. Intech Investment Management LLC increased its holdings in shares of Thermo Fisher Scientific by 19.4% in the second quarter. Intech Investment Management LLC now owns 3,142 shares of the medical research company’s stock worth $1,738,000 after purchasing an additional 510 shares during the last quarter. Brighton Jones LLC boosted its stake in Thermo Fisher Scientific by 5.9% during the second quarter. Brighton Jones LLC now owns 4,297 shares of the medical research company’s stock valued at $2,376,000 after buying an additional 240 shares during the last quarter. Ieq Capital LLC increased its stake in Thermo Fisher Scientific by 7.5% in the 2nd quarter. Ieq Capital LLC now owns 38,209 shares of the medical research company’s stock worth $21,130,000 after acquiring an additional 2,667 shares during the last quarter. Finally, GM Advisory Group LLC boosted its position in shares of Thermo Fisher Scientific by 2.0% during the 2nd quarter. GM Advisory Group LLC now owns 1,949 shares of the medical research company’s stock valued at $1,078,000 after acquiring an additional 38 shares during the last quarter. 89.23% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $530.26, for a total transaction of $5,302,600.00. Following the completion of the transaction, the chief executive officer now directly owns 111,192 shares of the company’s stock, valued at approximately $58,960,669.92. The trade was a 8.25 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Michael A. Boxer sold 2,000 shares of the stock in a transaction that occurred on Friday, October 25th. The shares were sold at an average price of $560.16, for a total transaction of $1,120,320.00. Following the completion of the sale, the senior vice president now directly owns 12,736 shares in the company, valued at approximately $7,134,197.76. This represents a 13.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 47,150 shares of company stock worth $25,954,465 over the last 90 days. Corporate insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Price Performance

TMO stock traded down $1.99 during mid-day trading on Friday, reaching $559.72. 2,134,669 shares of the company’s stock were exchanged, compared to its average volume of 1,426,114. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.63 and a quick ratio of 1.26. The company has a market cap of $214.09 billion, a price-to-earnings ratio of 35.09, a price-to-earnings-growth ratio of 3.59 and a beta of 0.76. The stock’s 50 day moving average is $529.80 and its 200 day moving average is $567.97. Thermo Fisher Scientific Inc. has a 12-month low of $493.30 and a 12-month high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.25 by $0.03. Thermo Fisher Scientific had a net margin of 14.48% and a return on equity of 17.49%. The business had revenue of $10.60 billion for the quarter, compared to the consensus estimate of $10.63 billion. During the same period last year, the firm posted $5.69 earnings per share. The company’s revenue was up .2% compared to the same quarter last year. On average, research analysts expect that Thermo Fisher Scientific Inc. will post 21.68 EPS for the current year.

Thermo Fisher Scientific declared that its board has approved a share repurchase plan on Friday, November 15th that allows the company to repurchase $4.00 billion in outstanding shares. This repurchase authorization allows the medical research company to repurchase up to 2% of its stock through open market purchases. Stock repurchase plans are usually an indication that the company’s board believes its stock is undervalued.

Thermo Fisher Scientific Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, January 15th. Investors of record on Friday, December 13th were paid a dividend of $0.39 per share. This represents a $1.56 annualized dividend and a yield of 0.28%. The ex-dividend date was Friday, December 13th. Thermo Fisher Scientific’s payout ratio is currently 9.78%.

Wall Street Analyst Weigh In

TMO has been the subject of a number of recent research reports. Stifel Nicolaus dropped their price objective on shares of Thermo Fisher Scientific from $680.00 to $665.00 and set a “buy” rating for the company in a research note on Thursday, October 24th. Redburn Atlantic initiated coverage on Thermo Fisher Scientific in a research note on Monday, October 14th. They set a “buy” rating and a $680.00 price target on the stock. Bank of America cut their target price on shares of Thermo Fisher Scientific from $675.00 to $660.00 and set a “buy” rating on the stock in a research report on Friday, December 13th. Bernstein Bank increased their price objective on shares of Thermo Fisher Scientific from $565.00 to $625.00 and gave the company a “market perform” rating in a research note on Tuesday, October 22nd. Finally, StockNews.com upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Tuesday. Four investment analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $648.95.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.